News
What’s happening in NF1 research today
Pipeline of experts advances discovery in neurofibromatosis
It can spawn tumors throughout the nervous system and bone deformities that riddle the whole body with pain. One of the most common rare diseases in the world, the genetic condition neurofibromatosis type 1, or NF1, can cause a wide spectrum of mild to severe symptoms—all stemming from a single mutation on a solitary gene: the NF1 gene on chromosome 17.
Read MoreNew Scholars Program to Support Early-Career NF1 Laboratory Scientists
In response to a critical funding gap affecting the NF1 research community, the Neurofibromatosis Therapeutic Acceleration Program (NTAP) has launched a new training initiative: the NF1 Basic and Translational Laboratory Scholars Program. This program is […]
Read More
Honoring the Immense Legacy of Dr. Vincent Riccardi: Through the lens of the Francis Collin’s Scholars
Dr. Vincent Riccardi is a foundational figure in the field of neurofibromatosis (NF) research. His dedication to understanding NF1 extended beyond tumor development—he recognized the broader, systemic impact of the condition and championed a whole-person […]
Read More
“In Their Own Words” NTAP Francis Collins Scholars’ Reflections on their Beloved Mentor, Dr. Vic Riccardi.
Angela Hirbe, MD, Ping Chi, MD, Peter de Blank, MD, Vincent Riccardi, MD, Francis Collins, MD, Matt Steensma, MD, Ashley Cannon, PhD., Miriam Bornhorst, MD, and Verena Staedtke, MD
Read More
An Exclusive Interview with Dr. Francis Collins on 10 Years of Advancing NF1 Research through NTAP’s Francis S. Collins Scholars Program
In this exclusive interview, Dr. Francis S. Collins, renowned geneticist and former Director of the National Institutes of Health, reflects on the impact of the Francis Collins Scholars (FCS) Program for Neurofibromatosis Type 1 (NF1) […]
Read More
The Impact of Mentorship and Collaboration in NF1 Research: An Interview with Dr. Shruti Garg and Dr. Steven Rhodes
Over the past ten years, the Francis Collins Scholars (FCS) Program has had a transformative impact on the careers of early-career researchers in the field of neurofibromatosis type 1 (NF1) and related disorders. In interviews […]
Read More
A Decade Of Impact The Francis Collins Scholars Program Is Driving The Future Of Nf1 Research
Baltimore, MD – In 2014, the Francis S. Collins Scholars Program (FCS) in Neurofibromatosis Clinical and Translational Research was launched to transform the landscape of NF1 research by attracting top clinician-scientists into the field. Named […]
Read More
NTAP’s Innovative Funding Approach Delivers Results
NTAP’s innovative funding approach was featured in an article,”Pedal to the Metal” on Inside Hopkins, the Johns Hopkins Medicine daily publication highlighting exceptional and impactful programs. “How an innovative funding approach is advancing research and […]
Read MoreRas Signaling Gone Awry: New Research Published on the Role of Ras in Cutaneous Neurofibroma Pathogenesis
The first manuscript from the NTAP 2022 Cutaneous Neurofibroma Symposium was published digitally by the Journal of Investigative Dermatology today. The paper RAS Signaling Gone Awry in the Skin: The Complex Role of RAS in […]
Read MoreThe 2022 Cutaneous Neurofibroma Symposium
A forum to identify priorities and advance the field of neurofibromatosis type-1 (NF1) research Introduction to NTAP symposiaNTAP convenes leading researchers and innovators from across multiple fields and scientific backgrounds in regular symposia to establish […]
Read More2021 Francis S. Collins Scholars Program in Neurofibromatosis Clinical and Translational Research Award Recipients Named
The Neurofibromatosis Therapeutic Acceleration Program (NTAP) at the Johns Hopkins University School of Medicine is proud to announce that Dr. Nicole Brossier, Dr. Suganth Suppiah, and Dr. Harish Vasudevan have been selected as the 2021 […]
Read More
FDA Approves First Therapy for Children with Debilitating and Disfiguring Rare Disease
For Immediate Release: April 10, 2020 Today, the U.S. Food and Drug Administration approved Koselugo (selumetinib) for the treatment of pediatric patients, 2 years of age and older, with neurofibromatosis type 1 (NF1), a genetic […]
Read More